Apimeds Pharmaceuticals US, Inc. (APUS)vsHaleon plc (HLN)
APUS
Apimeds Pharmaceuticals US, Inc.
$1.27
-9.93%
HEALTHCARE · Cap: $2.36M
HLN
Haleon plc
$9.12
+1.79%
HEALTHCARE · Cap: $40.34B
Smart Verdict
WallStSmart Research — data-driven comparison
HLN leads profitability with a 15.1% profit margin vs 0.0%. HLN earns a higher WallStSmart Score of 63/100 (C+).
APUS
Avoid22
out of 100
Grade: F
HLN
Buy63
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
0.6% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : APUS
The strongest argument for APUS centers on Debt/Equity, Price/Book.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : APUS
The primary concerns for APUS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
HLN is growing revenue faster at 0.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (63/100 vs 22/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apimeds Pharmaceuticals US, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company in the United States. The company is headquartered in Hopewell, New Jersey.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, formed as a spin-off from GlaxoSmithKline, that specializes in delivering innovative health solutions through its extensive portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. With a focus on key health segments such as oral care, pain relief, and dietary supplements, Haleon leverages strong brand recognition to meet the evolving needs of consumers. The company's commitment to sustainability and continuous innovation positions it strategically for long-term growth, aimed at enhancing health outcomes and delivering shareholder value through targeted investments and ongoing product development.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?